182 related articles for article (PubMed ID: 35095874)
1. Intralymphatic GAD-alum Injection Modulates B Cell Response and Induces Follicular Helper T Cells and PD-1+ CD8+ T Cells in Patients With Recent-Onset Type 1 Diabetes.
Barcenilla H; Pihl M; Wahlberg J; Ludvigsson J; Casas R
Front Immunol; 2021; 12():797172. PubMed ID: 35095874
[TBL] [Abstract][Full Text] [Related]
2. Glutamic Acid Decarboxylase Injection Into Lymph Nodes: Beta Cell Function and Immune Responses in Recent Onset Type 1 Diabetes Patients.
Casas R; Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J
Front Immunol; 2020; 11():564921. PubMed ID: 33162978
[TBL] [Abstract][Full Text] [Related]
3. Immune response differs between intralymphatic or subcutaneous administration of GAD-alum in individuals with recent onset type 1 diabetes.
Dietrich F; Barcenilla H; Tavira B; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2022 Mar; 38(3):e3500. PubMed ID: 34611978
[TBL] [Abstract][Full Text] [Related]
4. Intralymphatic glutamic acid decarboxylase administration in type 1 diabetes patients induced a distinctive early immune response in patients with DR3DQ2 haplotype.
Puente-Marin S; Dietrich F; Achenbach P; Barcenilla H; Ludvigsson J; Casas R
Front Immunol; 2023; 14():1112570. PubMed ID: 36817467
[TBL] [Abstract][Full Text] [Related]
5. Intralymphatic Glutamic Acid Decarboxylase-Alum Administration Induced Th2-Like-Specific Immunomodulation in Responder Patients: A Pilot Clinical Trial in Type 1 Diabetes.
Tavira B; Barcenilla H; Wahlberg J; Achenbach P; Ludvigsson J; Casas R
J Diabetes Res; 2018; 2018():9391845. PubMed ID: 30009185
[TBL] [Abstract][Full Text] [Related]
6. Long-lasting immune responses 4 years after GAD-alum treatment in children with type 1 diabetes.
Axelsson S; Chéramy M; Hjorth M; Pihl M; Akerman L; Martinuzzi E; Mallone R; Ludvigsson J; Casas R
PLoS One; 2011; 6(12):e29008. PubMed ID: 22174945
[TBL] [Abstract][Full Text] [Related]
7. A 1-year pilot study of intralymphatic injections of GAD-alum in individuals with latent autoimmune diabetes in adults (LADA) with signs of high immunity: No safety concerns and resemblance to juvenile type 1 diabetes.
Hals IK; Balasuriya C; Casas R; Ludvigsson J; Björklund A; Grill V
Diabetes Obes Metab; 2023 Nov; 25(11):3400-3409. PubMed ID: 37580967
[TBL] [Abstract][Full Text] [Related]
8. Decreased GAD(65)-specific Th1/Tc1 phenotype in children with Type 1 diabetes treated with GAD-alum.
Axelsson S; Hjorth M; Ludvigsson J; Casas R
Diabet Med; 2012 Oct; 29(10):1272-8. PubMed ID: 22587593
[TBL] [Abstract][Full Text] [Related]
9. The clinical and immunological significance of GAD-specific autoantibody and T-cell responses in type 1 diabetes.
Boettler T; Pagni PP; Jaffe R; Cheng Y; Zerhouni P; von Herrath M
J Autoimmun; 2013 Aug; 44():40-8. PubMed ID: 23770292
[TBL] [Abstract][Full Text] [Related]
10. Exhausted-like CD8+ T cell phenotypes linked to C-peptide preservation in alefacept-treated T1D subjects.
Diggins KE; Serti E; Muir V; Rosasco M; Lu T; Balmas E; Nepom G; Long SA; Linsley PS
JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33351781
[TBL] [Abstract][Full Text] [Related]
11. Early induction of GAD(65)-reactive Th2 response in type 1 diabetic children treated with alum-formulated GAD(65).
Axelsson S; Hjorth M; Akerman L; Ludvigsson J; Casas R
Diabetes Metab Res Rev; 2010 Oct; 26(7):559-68. PubMed ID: 20830731
[TBL] [Abstract][Full Text] [Related]
12. Intralymphatic GAD-Alum (Diamyd®) Improves Glycemic Control in Type 1 Diabetes With HLA DR3-DQ2.
Nowak C; Lind M; Sumnik Z; Pelikanova T; Nattero-Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Hanas R; Hernandez C; Clemente-León M; Gómez-Gila A; Ferrer Lozano M; Sas T; Pruhova S; Dietrich F; Puente-Marin S; Hannelius U; Casas R; Ludvigsson J
J Clin Endocrinol Metab; 2022 Aug; 107(9):2644-2651. PubMed ID: 35665810
[TBL] [Abstract][Full Text] [Related]
13. GAD-alum immunotherapy in type 1 diabetes expands bifunctional Th1/Th2 autoreactive CD4 T cells.
Arif S; Gomez-Tourino I; Kamra Y; Pujol-Autonell I; Hanton E; Tree T; Melandri D; Hull C; Wherrett DK; Beam C; Roep BO; Lorenc A; Peakman M
Diabetologia; 2020 Jun; 63(6):1186-1198. PubMed ID: 32248243
[TBL] [Abstract][Full Text] [Related]
14. GAD-alum treatment induces GAD65-specific CD4+CD25highFOXP3+ cells in type 1 diabetic patients.
Hjorth M; Axelsson S; Rydén A; Faresjö M; Ludvigsson J; Casas R
Clin Immunol; 2011 Jan; 138(1):117-26. PubMed ID: 21044870
[TBL] [Abstract][Full Text] [Related]
15. Intralymphatic Glutamic Acid Decarboxylase With Vitamin D Supplementation in Recent-Onset Type 1 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Phase IIb Trial.
Ludvigsson J; Sumnik Z; Pelikanova T; Nattero Chavez L; Lundberg E; Rica I; Martínez-Brocca MA; Ruiz de Adana M; Wahlberg J; Katsarou A; Hanas R; Hernandez C; Clemente León M; Gómez-Gila A; Lind M; Lozano MF; Sas T; Samuelsson U; Pruhova S; Dietrich F; Puente Marin S; Nordlund A; Hannelius U; Casas R
Diabetes Care; 2021 Jul; 44(7):1604-1612. PubMed ID: 34021020
[TBL] [Abstract][Full Text] [Related]
16. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with recent-onset type 1 diabetes: a randomised double-blind trial.
Wherrett DK; Bundy B; Becker DJ; DiMeglio LA; Gitelman SE; Goland R; Gottlieb PA; Greenbaum CJ; Herold KC; Marks JB; Monzavi R; Moran A; Orban T; Palmer JP; Raskin P; Rodriguez H; Schatz D; Wilson DM; Krischer JP; Skyler JS;
Lancet; 2011 Jul; 378(9788):319-27. PubMed ID: 21714999
[TBL] [Abstract][Full Text] [Related]
17. Specific Follicular Helper T Cell Signature in Takayasu Arteritis.
Desbois AC; Régnier P; Quiniou V; Lejoncour A; Maciejewski-Duval A; Comarmond C; Vallet H; Rosenzwag M; Darrasse-Jèze G; Derian N; Pouchot J; Samson M; Bienvenu B; Fouret P; Koskas F; Garrido M; Sène D; Bruneval P; Cacoub P; Klatzmann D; Saadoun D
Arthritis Rheumatol; 2021 Jul; 73(7):1233-1243. PubMed ID: 33538119
[TBL] [Abstract][Full Text] [Related]
18. GAD-specific T cells are induced by GAD-alum treatment in Type-1 diabetes patients.
Pihl M; Barcenilla H; Axelsson S; Chéramy M; Åkerman L; Johansson I; Ludvigsson J; Casas R
Clin Immunol; 2017 Mar; 176():114-121. PubMed ID: 28131926
[TBL] [Abstract][Full Text] [Related]
19. Role of Circulating T Follicular Helper Cells and Stem-Like Memory CD4
Ponnan SM; Vidyavijayan KK; Thiruvengadam K; Hilda J N; Mathayan M; Murugavel KG; Hanna LE
Front Immunol; 2021; 12():666388. PubMed ID: 33936106
[TBL] [Abstract][Full Text] [Related]
20. Follicular helper-T cells restore CD8
Niogret J; Berger H; Rebe C; Mary R; Ballot E; Truntzer C; Thibaudin M; Derangère V; Hibos C; Hampe L; Rageot D; Accogli T; Joubert P; Routy B; Harker J; Vegran F; Ghiringhelli F; Chalmin F
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34103351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
